EULAR 2021

Difficult to treat RA - hot topics and challenges

Early detection and treatment of RA

RA treatment - status and perspectives

Early detection of PsA & patient stratification

Update GRAPPA recommendations & axial PsA vs axSpA

Treatment decissions and therapeutic options in PsA

Definition of difficult to treat rheumatoid arthritis

Clinical outcome after switching between IL-6 and JAK inhibitors

Influence of comorbitidy on mortality

JAKi in real life!

Passive smoking in childhood and adulthood increases risk of RA

Switching of treatment from reference etanercept to sandoz etanercept biosimilar in patients with rheumatic diseases: Real-world interim data from the compact study

Recurrence of joint inflammation

Risk of cardiovascular events and disease activity

Using anti-TNF to deliver corticosteroids to inflammatory cells

Interstitial lung disease in patients with RA

RA activity and risk of complications after Arthroplasty

Vitamin D level in response to biologics

Où les arthrites récidivent-elles?

El tabaquismo pasivo aumenta el riesgo de padecer una artritis reumatoide

Påvirkning av komorbiditeter på mortalitet

Complications après arthroplastie selon l’activité du rhumatisme

Definición de artritis reumatoide difícil de tratar

Risiko for kardiovaskulære hendelser og sykdomsaktivitet

Vitamine D et réponse aux biomédicaments

Interstitiell lungesykdom hos pasienter med RA

JAKi dans la vraie vie!

Secukinumab: Adherence in PsA and AS

Role of Sex and Weight on PsA

GRAPPA Recommendations 2021

Deucravacitinib (TYK2 Inhibitor) in Psoriasis and Psoriatic Arthirtis

Power-Doppler ultrasound of the achilles tendon to differenciate exercise vs. inflammation

Hyperuricemia: increased risk of severe PsA course

Faeceal microbiota transplantation

Cardiovascular risk and metabolomic profiling in PsA

Secukinumab: Adhärenz bei PsA and AS

Rolle von Geschlecht und Gewicht

GRAPPA Empfehlungen 2021

Deucravacitinib (TYK 2 Inhibitor) neu bei PsA und Psoriasis

Power-Doppler-Sono AS: Differenzierung Belastung vs. Inflammation

Cave Hyperurikämie: Erhöhtes Risiko für schweren Verlauf

Kardiovaskuläres Risiko und metabolomisches Profil bei PsA

Impact of sex on BASDAI scores

Do patients with axSpA help us?

Non-radiographic or radiographic axial SpA - does it matter?

Feasibilty of anti-TNF tapering in low disease activity: The SPACING trial

Radiographic progression in axSpA

Impatto del sesso sugli score del BASDAI

¿Nos ayudan los pacientes con espondiloartritis axial?

fattibilità della riduzione del dosaggio degli anti-TNF in pazienti con AxSpA e bassa attività di malattia: il trial SPACING

Progresión radiográfica en espondiloartritis axial

Outcome of Covid-19 in Rheumatoid Arthritis under Advanced Therapy

Risk factors of COVID-19 course in SLE

COVID-19 outcome in inflammatory arthropathy patients

Immunogenicity of mRNA-COVID-19 vaccine in patients with inflammatory rheumatic disease

Influence of TNF-Inhibition on COVID-19

Rituximab and COVID-19 (Nat. French Registry Study)

Rituximab and COVID-19 (Multicenter-Study)

COVID-19 Vaccination in patients with rheumatic disease

Immunogenicidad de la vacuna mRNA-COVID-19 en pacientes con enfermedades reumáticas inflamatorias

SARS-CoV2-Impfung bei Rheumapatienten

Patientenumfrage während der Pandemie

COVID-19 bei SLE

Einfluss von TNF-Blockern auf COVID-19-Verlauf

Rituximab bei COVID-19 (franz. Registerdaten)

Rituximab bei COVID-19 (Multicenter-Studien)

New therapy for cutaneous manifestations

Convincing Anifrolumab data on efficacy and drug tolerance

Combination of Belimumab and Rituximab is beneficial

Neue Therapie für kutane Manifestationen

Anifrolumab in Wirksamkeit und Verträglichkeit überzeugend

Kombination Belimumab und Retuximab vorteilhaft

Efficcacy and Safety of TNF-α Blockers and Tocilizumab in Takayasu Arteritis

What is new in Giant Cell Arteritis?

Tocilizumab Monotherapy for Giant Cell Arteritis - the GUSTO trial

Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis

Efficacia e sicurezza degli anti-TNF e del tocilizumab nella arterite di Takayasu

Monoterapia con tocilizumab nella arterite a cellule giganti – il trial GUSTO

Lung involvement: diagnostic work-up and  new treatment modalities

Risk factors for ADAb formation: Data from the NOR-DRUM A trial

Therapeutic drug monitoring and immunogenicity

Secukinumab in patients with rotator cuff tendinopathy

Fatigue in Arthritis, SpA & systemic rheumatic diseases

Lyme disease: Myths and reality

Co nowego w reumatologii dziecięcej

Factores de riesgo del desarrollo de anticuerpos anti-infliximab.: resultados del ensayo NOR-DRUM A

Therapeutic drug monitoring (TDM) og immunogenisitet

EULAR, najnowsze postępy w reumatologii